The use of atypical antipsychotics as augmentation for treatment-resistant major depressive disorder

Primary Psychiatry

Volumn 15, Issue 11, 2008, Pages 44-47

  Papakostas, George I ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CITALOPRAM; DOPAMINE RECEPTOR; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; GLUCOSE; NORADRENALIN; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONIST; SERTRALINE; TRIACYLGLYCEROL; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; NEUROPHARMACOLOGY; PERIPHERAL EDEMA; PROLACTIN BLOOD LEVEL; QT INTERVAL; RECEPTOR AFFINITY; REMISSION; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

EID: 61949209836     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75(3):139-153.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
3. Papakostas GI. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol. 2005;6(4):209-220.
4. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors, focus on newer generation compounds. Life Science. 2000;24;68(1):29-39.
5. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411.
6. Schmidt AW, Lebel A, Howard HR Jr, Zom SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201.
7. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389.
8. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-134.
9. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289-1297.
10. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364-372.
11. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236.
12. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593-602.
13. Keitner GI, Garlow SJ, Ryan CE, et al. Risperidone augmentation for patients with difficult-to-treat major depression. Paper presented at: the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
14. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487-494.
15. Khullar A, Chokka P, Fullerton D, McKenna S, Blackman A. Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: double blind, randomized, placebo controlled study. Paper presented at: the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
16. Mattingly GW, Ilivicky HJ, Canale JP, Anderson RH. Quetiapine augmentation for treatment-resistant depression. Paper presented at: 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
17. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826-831.
18. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161-1172.
19. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530.
20. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531- 1541.
21. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
22. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
23. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004b;65(2):217-221.
24. ClinicalTrials.gov. Available at: www.clinicaltrials.gov. Accessed September 15, 2008.
25. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505-2513.